References
- Drozda K, Pacanowski MA. Clinical trial designs to support clinical utility of pharmacogenomic testing. Pharmacotherapy. 2017;37(9):1000–1004. doi: 10.1002/phar.1971
- PharmGKB. PharmGkb. [cited 2023 Jul 18]; Available from: https://www.pharmgkb.org/
- Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics. 2013;14(9):1085–1097. doi: 10.2217/pgs.13.81
- EMA. ICH E16 genomic biomarkers related to drug response: context, structure and format of qualification submissions - scientific guideline. European Medicines Agency. Published 2018 September 17, [cited 2023 Nov 11]; Available from: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions
- Clinical Trials - Regulation EU No 536/2014. Published 2023 Jul 19, . [cited 2023 Aug 8]; Available from: https://health.ec.europa.eu/medicinal-products/clinical-trials/clinical-trials-regulation-eu-no-5362014_en
- EMA. Good pharmacogenomic practice - scientific guideline European Medicines Agency. European Medicines Agency. 2018. [cited 2023 Aug 7]; Available from: https://www.ema.europa.eu/en/good-pharmacogenomic-practice-scientific-guideline
- EMA. Use of pharmacogenetic methodologies in the pharmacokinetic evaluation medicinal products - scientific guideline European Medicines Agency. European Medicines Agency. 2012. [cited 2023 Aug 7]; Available from: https://www.ema.europa.eu/en/use-pharmacogenetic-methodologies-pharmacokinetic-evaluation-medicinal-products-scientific-guideline
- EMA. Pharmacogenomic samples, testing and data handling - scientific guideline European Medicines Agency. European Medicines Agency. 2007. [cited 2023 Aug 7]; Available from: https://www.ema.europa.eu/en/pharmacogenomic-samples-testing-data-handling-scientific-guideline
- EMA. Pharmacogenomics In Oncology - Scientific Guideline European Medicines Agency. European Medicines Agency. 2008. [cited 2023 Aug 8]; Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmacogenomics-oncology_en.pdf
- Concept paper on predictive biomarker-based assay development in the context of drug development and lifecycle. [cited 2023 Aug 7]; Available from: https://www.ema.europa.eu/en/predictive-biomarker-based-assay-development-context-drug-development-lifecycle
- Reflection paper on methodological issues associated with pharmacogenomic biomarkers in relation to clinical development and patient selection. Published online 2011. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-issues-associated-pharmacogenomic-biomarkers-relation-clinical_en.pdf
- Clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. Clin Pharmacol. Published online 2013 Jan; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacogenomics-premarket-evaluation-early-phase-clinical-studies-and-recommendations
- New template - compliance with applicable rules for biological samples. [cited 2023 Aug 8]; Available from: https://health.ec.europa.eu/latest-updates/new-template-compliance-applicable-rules-biological-samples-2022-02-01_en
- EUR-Lex - 32016R0679 - EN - EUR-Lex. [cited 2023 Aug 8]; Available from: https://eur-lex.europa.eu/eli/reg/2016/679/oj
- Opinion 3/2019 concerning the questions and answers on the interplay between the clinical trials regulation (CTR) and the General data protection regulation (GDPR) | European data protection board. [cited 2023 Aug 8]; Available from: https://edpb.europa.eu/our-work-tools/our-documents/opinion-art-70/opinion-32019-concerning-questions-and-answers_en
- Question and answers on the interplay between the clinical trials regulation and the General data protection regulation. [cited 2023 Aug 29]; Available from: https://health.ec.europa.eu/system/files/2019-04/qa_clinicaltrials_gdpr_en_0.pdf
- Schuck RN, Florian J, Charlab R, et al. Trial geography, pharmacogenetics, and global drug development. Clin Pharmacol Ther. 2015;97(3):218–220. doi: 10.1002/cpt.27
- Wen JG, Wu L, Pu, XX, et al. Pharmacogenomics research: a potential strategy for drug development. Pharm. 2015;70(7):437–445.
- Roses AD, Saunders AM, Lutz MW, et al. New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol. 2014;14:81–89. doi: 10.1016/j.coph.2013.12.002
- Bienfait KL, Shaw PM, Murthy G, et al. Mobilizing pharmacogenomic analyses during clinical trials in drug development. Pharmacogenomics. 2013;14(10):1227–1235. doi: 10.2217/pgs.13.109
- Cabaleiro T, Prieto-Pérez R, Ochoa D, et al. Application of pharmacogenomics and other new technologies to drug development. Med Clin. 2013;140(12):558–563. doi: 10.1016/j.medcli.2013.02.010
- Potential of adaptive clinical trial designs in pharmacogenetic research - PubMed. [cited 2023 Aug 8]; Available from: https://pubmed.ncbi.nlm.nih.gov/22462749/
- Franc MA, Cohen N, Warner AW, et al. Coding of DNA samples and data in the pharmaceutical industry: current practices and future directions–perspective of the I-PWG. Clin Pharmacol Ther. 2011;89(4):537–545. doi: 10.1038/clpt.2010.306
- Stingl Kirchheiner JC, Brockmöller J. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs. Clin Pharmacol Ther. 2011;89(2):198–209. doi: 10.1038/clpt.2010.274
- Dal-Ré R, Luque I, Torres R, et al. Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees. Pharmacogenomics J. 2009;9(2):86–89. doi: 10.1038/tpj.2008.18
- Akkari PA, Swanson TW, Crenshaw DG, et al. Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development. Curr Pharm Des. 2009;15(32):3754–3763. doi: 10.2174/138161209789649538
- Lesko LJ, Salerno RA, Spear BB, et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe workshop. J Clin Pharmacol. 2003;43(4):342–358. doi: 10.1177/0091270003252244
- Ferentz AE. Integrating pharmacogenomics into drug development. Pharmacogenomics. 2002;3(4):453–467. doi: 10.1517/14622416.3.4.453
- Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov. 2002;1(4):300–308. doi: 10.1038/nrd771
- Nogueiras-Álvarez R. Pharmacogenomics in clinical trials: an overview. Front Pharmacol. 2023 [cited 2023 Nov 11];14. doi: 10.3389/fphar.2023.1247088
- Arbitrio M, Scionti F, Di Martino MT, et al. Pharmacogenomics biomarker discovery and validation for translation in clinical practice. Clin Transl Sci. 2021;14(1):113–119. doi: 10.1111/cts.12869
- Ehmann F, Caneva L, Papaluca M. European Medicines Agency initiatives and perspectives on pharmacogenomics. Br J Clin Pharmacol. 2014;77(4):612–617. doi: 10.1111/bcp.12319
- Rodriguez A, Tuck C, Dozier MF, et al. Current recommendations/practices for anonymising data from clinical trials in order to make it available for sharing: a scoping review. Clin Trials Lond Engl. 2022;19(4):452–463. doi: 10.1177/17407745221087469